Ovid Therapeutics OVID Institutional Ownership

Ovid Therapeutics Inc. (NASDAQ:OVID) is held by 132 institutional investors per 13F filings through June 2026.

• Their combined ownership stood at 74.7% of outstanding shares in June 2026, down from 77.2% in March 2026.
• Their total shares held in OVID increased 65.39% from the prior quarter, while the number of investors in Ovid Therapeutics increased 88.57% year over year.
• Activity in OVID broke down as 81 buyers, 27 sellers, and 24 unchanged among 132 total holders.
• In total, institutional investors held 147.45Mn shares in Ovid Therapeutics as of June 2026, up by 58.3Mn shares quarter on quarter, and up 111.49Mn shares year over year.
• Jupiter Topco LLC holds the largest position in OVID at 20.74Mn shares as of June 30, 2026, or 10.5% of shares outstanding.
• The most significant purchases of OVID for the quarter ending June 2026 came from Jupiter Topco LLC (20.74Mn), BlackRock, Inc. (9.29Mn), State Street Corp (7.38Mn), BRAIDWELL LP (5.92Mn), ADAR1 Capital Management, LLC (2.87Mn).
• Leading sellers of Ovid Therapeutics shares for the quarter ending June 2026 were Saturn V Capital Management LP (3.5Mn), Ally Bridge Group (NY) LLC (2.19Mn), SUSQUEHANNA INTERNATIONAL GROUP, LLP (1.88Mn), MILLENNIUM MANAGEMENT LLC (1.46Mn), RENAISSANCE TECHNOLOGIES LLC (998.8K).
• Business Quant data shows the 10 biggest positions in Ovid Therapeutics as of June 2026 are held by Jupiter Topco LLC (20.74Mn), EVENTIDE ASSET MANAGEMENT, LLC (11.81Mn), BlackRock, Inc. (10.82Mn), RA CAPITAL MANAGEMENT, L.P. (10.5Mn), Affinity Asset Advisors, LLC (10.14Mn), State Street Corp (7.9Mn), VANGUARD CAPITAL MANAGEMENT LLC (7.76Mn), ADAR1 Capital Management, LLC (7.42Mn), BALYASNY ASSET MANAGEMENT L.P. (6.72Mn), ADAGE CAPITAL PARTNERS GP, L.L.C. (6.16Mn).